Strong Revenue Growth:
Feedback suggests revenue expanded rapidly, highlighted by a first-place ranking in the FT’s 2026 Americas’ Fastest-Growing Companies based on 2021–2024 growth and a reported $617.4M in 2024 revenue. Additional signals include reported surges in appointments and broader commercial activity across 2025–2026.
Investor Backing & Capital Strength:
Feedback suggests substantial access to capital, including a $150M Series D in March 2026 and cumulative funding of about $328M. This capital appears to support expansion into insurers, employers, and health-system partnerships.
Market Expansion:
Feedback suggests the company expanded distribution via 125+ health-plan partners (later 135), employer benefits, and health-system integrations. These channels appear to broaden reach beyond direct patient acquisition.
.png)
.png)
